Kersten Woodlee
Psychiatric/Mental Health · Nashville, TNNPI 1154560555
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 577 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 577 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$1K
- Johnson & Johnson$1K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Neurocrine Biosciences, Inc.$947
- plus $2K from 15 others
What the payments were for
- Food & beverage$9,99299%
- Education$731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 69 | $1,597 |
| Alkermes, Inc. | 74 | $1,471 |
| Johnson & Johnson | 98 | $1,438 |
| Teva Pharmaceuticals USA, Inc. | 80 | $1,207 |
| AbbVie | 85 | $1,108 |
| Neurocrine Biosciences, Inc. | 51 | $947 |
| Otsuka America Pharmaceutical, Inc. | 32 | $627 |
| Vanda Pharmaceuticals Inc. | 15 | $347 |
| E.r. Squibb & Sons, L.L.C. | 15 | $266 |
| Sunovion Pharmaceuticals Inc. | 15 | $255 |
| Lundbeck LLC | 12 | $246 |
| Indivior Inc. | 12 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $111 |
| Jazz Pharmaceuticals Inc. | 3 | $62 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Noven Therapeutics, LLC | 2 | $45 |
| Bausch Health US, LLC | 1 | $23 |
| Biogen | 1 | $19 |
| Tris Pharma Inc | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Harmony Biosciences LLC | 1 | $12 |
How this compares
$10,065 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 57 | $468,694 |
| Austedo XrDeutetrabenazine | 14 | $191,877 |
| Risperdal ConstaRisperidone Microspheres | 38 | $101,001 |
| Invega SustennaPaliperidone Palmitate | 33 | $93,813 |
| CaplytaLumateperone Tosylate | 36 | $61,906 |
| RexultiBrexpiprazole | 39 | $56,214 |
| VraylarCariprazine Hcl | 27 | $37,662 |
| LybalviOlanzapine/Samidorphan Malate | 20 | $31,326 |
| Abilify MaintenaAripiprazole | 12 | $25,293 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 74 | $9,462 |
| Paliperidone ErPaliperidone | 19 | $9,130 |
| Clozapine | 93 | $6,526 |
| BelsomraSuvorexant | 15 | $5,837 |
| QuviviqDaridorexant Hcl | 12 | $5,833 |
| Methylphenidate ErMethylphenidate Hcl | 13 | $5,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $947 | $468,69457 claims |
| Johnson & JohnsonRisperdal Consta, Invega Sustenna | $1,438 | $194,81471 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,207 | $191,87714 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $627 | $81,50751 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,597 | $61,90636 claims |
| AbbVieVraylar | $1,108 | $37,66227 claims |
| Alkermes, Inc.Lybalvi | $1,471 | $31,32620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Nashville
- Kristian DambrinoNashville$449K
- Lauren HansenNashville$263K
- Aaron JonesNashville$20K
- Kathleen McCoyNashville$12K
- Preeti SrivastavaNashville$11K
- Ariel NewtonNashville$10K
- Robert McKeownNashville$10K
- Debra YorkNashville$9K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.